IN THE FETAL SHEEP, both hyperplasia and hypertrophy of cardiac myocytes occur in utero; after birth there is both loss of cardiac myocytes and myocyte hypertrophy (2) . In mice, overexpression of insulin-like growth factor (IGF)-I is associated with increased heart weight and cardiac myocyte number (20) . Similar effects are seen in the sheep, because administration of IGF-I to fetal sheep for 1 wk in late gestation is associated with increased heart-to-body weight ratio and an increase in left ventricle (LV) weight (14) . Administration of the potent analog long R3 IGF-I, which has a low affinity for IGF-I binding proteins (IGFBPs), to the fetal sheep for 7 days in late gestation stimulated cardiac growth by hyperplasia, reducing the percentage of binucleated cells in both LV and right ventricle (RV) from ϳ61% to 46% (21) . Long R3 IGF-I also increased 5-bromo-2Ј-deoxyuridine (BrdU) uptake three-to fivefold in isolated fetal sheep cardiomyocytes in culture, suggesting that myocyte proliferation was stimulated. These actions were mediated through ERK and phosphatidylinositol 3-kinase signaling pathways (21) .
We wished to determine the effects of intrafetal infusions of native IGF-I on fetal cardiomyocytes with shorter periods of infusion. We particularly wanted to see whether any effects associated with IGF-I treatment persist after cessation of the IGF-I infusion because it is possible that physiological demands on the fetal heart could override any acute growthstimulating effects of IGF-I once it is withdrawn.
Our hypothesis was that IGF-I treatment would persistently alter fetal heart weight and cardiomyocyte growth and division. We report that there is sexual dimorphism in the morphology of cardiac myocytes in the fetal sheep in late gestation and in the hypertrophic response to IGF-I, which occurred in males but not females.
METHODS
The Animal Care and Ethics Committee of the University of New South Wales approved these experiments.
Surgery. Briefly, at 118 days of gestation, ewe and fetus were anesthetized by intravenous injection to the ewe of 1-2 g thiopental sodium (Pentothal, Abbott Australasia). Anesthesia was maintained with 2-3% halothane (Fluothane, Zeneca) in oxygen. At 118 days of gestation (term ϭ 150 days), polyvinyl catheters (1.0-mm ID, 1.5-mm OD) were inserted into a fetal femoral artery and both tarsal veins. An amniotic catheter (1.5-mm ID, 2.7-mm OD) was sutured on the skin of the fetuses. Two growth measurements were made. A suture was placed in the skin overlying the spine approximately at the 12th rib. Another suture was placed in the skin overlying the spine at the base of the tail. With the fetus in the prone position, the distance between these two sutures (longitudinal measure) was measured in duplicate. The distance around the chest at the level of the 12th thoracic vertebra (chest girth) was also measured in duplicate. The percent increase in both of these measurements was calculated at postmortem. A maternal femoral artery and vein were also catheterized. Eighty milligrams of gentamicin sulfate (2 ml Gentam, Troy Laboratories) and 600 mg of procaine penicillin (1.6 ml Illum Propen, Troy Laboratories) were placed in the amniotic cavity and given intramuscularly to the ewe. The same dose was also administered into the amniotic cavity once daily for at least 2 days after surgery (14) .
Ewes were housed in individual metabolic cages at 18 -22°C. They had free access to tap water and were fed 1,200 g of lucerne chaff and 300 g of oats each day. Fetal vascular catheters were flushed daily with 4 ml of heparinized saline (heparin injection, Pharmacia & Upjohn, 100 IU heparin/ml saline).
Experimental protocol. From day 0 (121 days gestation), fetuses were infused with either IGF-I or vehicle via a tarsal vein for ϳ100 h. Eight fetuses received recombinant human IGF-I (GroPep, Adelaide, Australia; animal/media grade) at 0.08 mg/h in a volume of 0.19 ml/h. Seven fetuses received vehicle at the same rate. IGF-I was dissolved in 0.1% bovine serum albumin (BSA) (Sigma; radioimmunoassay grade); 0.1% BSA in 0.15 M saline was prepared in bulk, filter sterilized, and stored in aliquots at Ϫ20°C until the day of use. Infusates were prepared on the day of use and changed every 48 h. They were delivered through a filter with a pore size of 0.2 m (Acrodisc Syringe Filters, Pall; see Refs. 12 and 14).
On day 3 of infusion, 250 mg of BrdU (catalog no. B9285-1G, Sigma) dissolved in 16.5 ml of heparinized saline was infused into a fetal tarsal vein with a Braun Perfusor VI infusion pump at the rate of 33 ml/h for 30 min through a 0.2-m filter. The BrdU solution was heated and filtered to make sure it was in solution, and we did not observe any precipitation in the catheter or infusion apparatus. BrdU is an analog of thymidine and is incorporated into newly synthesized DNA instead of thymidine (18) . Doses used were based on estimated fetal weight after reference to Greenwood et al. (7) and Carbajo et al. (3) .
Because we showed previously that IGF-I has no acute or chronic effects on blood pressure or heart rate, we only measured fetal arterial pressure, heart rate, and intra-amniotic pressure for 1 h on day 4, using methods already described (14, 15) , and the IGF-I/vehicle infusion was then stopped in the early afternoon. Animals were killed on day 7.
Fetal arterial blood samples were taken before, during, and after infusion to monitor arterial PO 2, PCO2, pH, hematocrit (Hct), and levels of glucose and lactate. Arterial PO2, PCO2, pH, glucose, and lactate were measured at 37°C and corrected to 39.5°C with a blood gas analyzer (ABL 715, Radiometer Pacific). Hct was determined in duplicate (Haematokrit, Hettich), immediately before the infusion began and on days 2, 4, and 7. Blood was centrifuged for 10 min at 2,500 rpm and 4°C. Plasma was stored at Ϫ20°C for measurement of plasma IGF-I.
Ewes were killed on day 7 of the experiment, at 128 days of gestation, by intravenous injection of 4 -5 g of pentobarbital sodium (Lethabarb, Virbac). Once fetal weight and girth were measured, the fetal heart was removed and processed for confocal microscopy (2, 13) and fluorescence-activated cell sorting (FACS). After the heart was removed, fetal sex, nose-to-rump length, and organ weights were recorded. Tissues were snap-frozen in liquid nitrogen and stored at Ϫ80°C for further analysis.
There were 11 control fetuses, seven of which received infusions of vehicle. These were four female and three male fetuses of which five were singletons and two were twins. Four control fetuses did not receive an infusion of vehicle. These were three females and one male; all four were twin fetuses: three were twins of IGF-I-infused fetuses and one was the twin of a vehicle-infused fetus. Addition of these untreated fetuses to the control group did not affect the profile of myocyte measurements of vehicle-treated fetuses. For analysis of cardiac myocytes, untreated fetuses were included in the control group together with vehicle-infused fetuses. Eight fetuses received IGF-I infusions, comprising four males and four females, of which four were singleton and four twin fetuses.
Preparation of cardiac myocytes. Small blocks (ϳ1 cm 3 ) of RV and LV free walls (FW) extending from the epicardium to the endocardium were dissected midway between the atrioventricular groove and the apex of the heart. The remaining tissue was frozen in liquid nitrogen and stored at Ϫ80°C for later analysis.
The blocks of myocardium were sliced (Vibroslicer 752, Campden Instruments, speed 9) into 400-m-thick sections. Myocytes were isolated by a method already described (2, 13) . Briefly, slices of RVFW and LVFW were immersed in cold Ca-Krebs that had been aerated with carbogen (5% CO 2 in oxygen, BOC Gases, Lidcombe, NSW, Australia) and digested for 14 min at 37°C with collagenase (type 2, 305 U/ml, Worthington Biochemical). The digestion was stopped, and cells were treated with relaxing solution (in mM: 117 KCl, 36 NaCl, 1 MgSO4, 60 HEPES, 8 ATP disodium, 50 EGTA, pH 7.0) and ethidium bromide to stain nuclei (2, 13) . Cells were examined with a Leica TCS NT laser scanning confocal microscope (Leica Microsystems, Heidelberg, Germany) equipped with an argon ion laser and coupled to an inverted microscope with a C-Apochromat (ϫ63) water-immersion objective lens. Fluorescence was excited at 488 nm, and the fluorescein isothiocyanate (FITC) absorbance setting was selected to detect fluorescence over the range 520 -675 nm. The proportions of uninucleated and binucleated cardiac myocytes in the RVFW and LVFW from each fetus were determined by counting 200 cells from each ventricle.
To measure the volumes of individual myocytes, undamaged uninucleated or binucleated myocytes were selected. Only relaxed myocytes, which have visible striations in the cytoplasm, a clearly defined cell membrane, and no evidence of cytoplasmic vacuoles, were measured ( Fig. 1 ; see also Refs. 2 and 13). Methods for determining myocyte volumes have been described previously (2, 13) . This method of measuring cell volume has a coefficient of variation of 2.5% (2) as assessed by measurement of the volumes of five individual myocytes independently by three separate investigators. In each of 10 control fetuses, an average of 62 Ϯ 5 (SE) myocytes were measured; in each of eight IGF-I infused fetuses, 59 Ϯ 7 myocytes were measured.
Fluorescence-activated cell sorting. Two slices per ventricle were also digested as above without ethidium bromide staining. They were fixed with 70% ethanol and stored at Ϫ20°C. On the day of use, cells were defrosted and nuclei were extracted as described by Poolman et al. (18) . Briefly, the nuclear pellet was treated with 2 ml of 2 M HCl to denature DNA into single strands. The nuclei were labeled with anti-BrdU-FITC, treated with RNase, and stained with propidium iodide (PI). BrdU uptake was measured in four control and four IGF-I-treated fetuses, and cell cycle activity was measured in six control and seven treated fetuses. PI binds to DNA strands via intercalation. FACS was performed on a FACScan cytometer running HPLC separation and radioimmunoassay of plasma IGF-I. Plasma IGF-I was measured by radioimmunoassay (RIA) after separation of IGF and IGFBP by size-exclusion HPLC at pH 2.5 (16) . One hundred fifty microliters of acidified, defatted, filtered 15% plasma was injected (Shimadzu SIL-9A) onto a Waters Protein Pak 125 HPLC column (Waters Millipore, Lane Cove, NSW, Australia) equilibrated at 1 ml/min with 200 mM acetic acid, 50 mM trimethylamine, 0.05% Tween 20 at pH 2.5 (chromatography mobile phase). All samples were run in two HPLC runs, with mean recovery of 125 I-labeled IGF-I from the column of 98.3 Ϯ 1.4% (SE). Four fractions of eluate were routinely collected for each acidified plasma specimen, at times determined by elution of 125 I-IGF-I and IGF-I immunoreactivity. Fractions containing IGF-I were collected from 9.25 to 11.75 min after injection.
HPLC fractions collected were neutralized with 0.6 vols of 0.4 M Tris base before analysis. Plasma IGF-I concentrations were obtained by analysis of neutralized HPLC fraction, in a RIA specific for IGF-I (n ϭ 2 assays). This assay uses a rabbit polyclonal antibody raised against recombinant human IGF-I (GroPep), and recombinant human IGF-I (GroPep) as standard and radioligand.
125 I-IGF-I (specific activity 58 Ci/g) was prepared by iodinating recombinant human IGF-I with [
125 I]NaCl (Amersham Biosciences) and chloramine-T. Inter-and intra-assay coefficients of variation (CV) for a fraction eluate pool were 10.8% and 5.0%, respectively. Covariance for extraction and assay of a fetal QC plasma included in each HPLC run and containing 118 ng/ml of IGF-I was 1.3% (n ϭ 2 HPLC runs).
Data analysis and statistics. Data were analyzed with the statistical software program SPSS for Windows (version 15, SPSS). Ratios and derived variables were also calculated with this program. Univariate analysis with treatment, sex, and twinning as fixed factors was carried out. If there was a significant interaction between treatment and sex, then data were treated with a post hoc unpaired t-test. The effects of IGF-I on myocyte volumes were subjected to the same analysis, but fetus was included as a covariate, since the volumes of a number of myocytes in each subtype from each heart were measured. Statistical significance was set at P Յ 0.05.
RESULTS

Fetal plasma IGF-I and fetal growth.
Intrafetal IGF-I infusion increased fetal plasma IGF-I by ϳ175% after 2 days and by ϳ100% at the end of the 4-day infusion compared with control fetuses (Fig. 2) . Plasma IGF-I levels before and at 3 days after the infusion were similar in control and IGF-Iinfused fetal sheep.
IGF-I did not alter fetal body weight (control: 3.1 Ϯ 0.1 kg, IGF-I: 3.1 Ϯ 0.2 kg), nose-to-rump length (control: 57.9 Ϯ 0.9 cm, IGF-I: 58.0 Ϯ 0.9 cm), girth [control: 33.9 Ϯ 0.7 cm (n ϭ 9), IGF-I: 33.5 Ϯ 0.9 cm], or the rates of increase in chest girth and length measured from the day of surgery to the day of postmortem (data not shown).
In male fetuses, IGF-I treatment was associated with increased spleen weights (P Ͻ 0.05; Fig. 3 ) and spleen-to-body weight ratios compared with control fetuses. This effect was not seen in female fetuses. IGF-I was associated with increased combined kidney weights in both male and female fetuses (P Ͻ 0.05; Fig. 3 ) but not kidney weight-to-total body weight ratios (P ϭ 0.055), possibly because of an interaction between twinning and IGF-I treatment (P Ͻ 0.05). There were no differences between male and female fetal heart weights. IGF-I treatment did not alter total heart weight ( Fig. 3) , weight of LVFW, RVFW, or interventricular septum (IVS), or combined atrial weight of either male or female fetuses compared with control fetuses (Table 1) . Similarly, IGF-I did not alter the heart weight-to-body weight ratio or the ratios of LVFW, RVFW, IVS, or atrial weights to body weight (Table 1) . IGF-I treatment was not associated with changes in adrenal weights (control: 0.4 Ϯ 0.03 g, IGF-I: 0.4 Ϯ 0.02 g), liver weights (Fig.  3) , or total cotyledonary mass or the distribution of cotyledon subtypes in the placenta (data not shown).
IGF-I treatment and cardiac myocytes. The percentage of myocytes that were uninucleated was higher in the RV compared with the LV of female fetuses (P ϭ 0.026, n ϭ 10), control fetuses (P ϭ 0.003, n ϭ 8), and fetuses that were singletons (P ϭ 0.003, n ϭ 9). If fetuses were male or twins or received IGF-I treatment, the percentages of myocytes that were uninucleated were the same in the RVFW and the LVFW.
In female fetuses the proportion of uninucleated cardiac myocytes in the LVFW was lower and the proportion of binucleated myocytes was higher than in males (Fig. 4) . In the RVFW this difference in the proportion of myocytes that were uninucleated did not reach significance [males: control 60 Ϯ 4% (n ϭ 4), IGF-I treatment 51 Ϯ 4% (n ϭ 4); females: control 49 Ϯ 4% (n ϭ 6), IGF-I treatment 47 Ϯ 2% (n ϭ 4)]. IGF-I did not alter the percentage of myocytes that were uninucleated compared with control fetuses.
Both bi-and uninucleated myocytes were smaller in the LVFW compared with the RVFW of both sexes (P Ͻ 0.002, n ϭ 10 females, n ϭ 8 males; Fig. 5 ). In both sexes binucleated myocytes from either ventricle were larger than uninucleated myocytes (P Ͻ 0.001, n ϭ 10 females, n ϭ 8 males).
IGF-I had sex-specific effects on the volume of fetal myocytes. In control fetuses, the volumes of all four subtypes of myocytes (i.e., uni-and binucleated myocytes isolated from RVFW and LVFW) of females were larger than those in males (P Ͻ 0.001; Fig. 5 ). All four myocyte subtypes (RV and LV uni-and binucleated cells) in IGF-I-treated males were larger than those isolated from control males (P Յ 0.006), but this was not the case for IGF-I-treated females (Fig. 5) .
Effect of IGF-I on cell cycle activity. IGF-I treatment had no effect on the incorporation of BrdU but was associated with a nonsignificant reduction in the percentage of nuclei from the RVFW that were in G 0 and G 1 and an increase in the percentage in G 2 and M phases of the cell cycle compared with vehicle-infused fetuses (P Յ 0.1; Table 2 ). IGF-I reduced the percentage of nuclei from the LVFW that were in S phase compared with vehicle-infused fetuses (P ϭ 0.01; Table 2 ). There were no differences in the cell cycle activity profile of male and female fetuses, nor were there any interactions between sex and treatment.
Effects of IGF-I on blood pressure, heart rate, blood gases, pH, and metabolites. IGF-I treatment was associated with lower fetal systolic pressures compared with vehicle-infused fetuses (P Ͻ 0.05), but diastolic and mean arterial pressures and heart rates were similar (Table 3) . IGF-I also did not alter the rate-pressure product, nor were there any differences between control males and females in the rate-pressure product [7, 787 Ϯ 800 and 7,705 Ϯ 393 mmHg ⅐ beats/min (bpm), respectively]. However, in IGF-I-treated fetal sheep, females had a higher mean rate-pressure product (9,113 Ϯ 554 mmHg ⅐ bpm) than males (6,815 Ϯ 428 mmHg ⅐ bpm; P Ͻ 0.03).
IGF-I did not alter fetal arterial PO 2 , PCO 2 , pH, or glucose. Hct of vehicle-infused fetuses were higher before the start of Fig. 3 . Effects of IGF-I on fetal spleen (A), kidney (B), heart (C), and liver (D) weights in male (hatched bars) and female (filled bars) fetal sheep. Spleen weight and spleen-to-body weight ratios were increased by IGF-I in male fetuses only. IGF-I increased kidney weight in male and female fetuses and did not affect heart or liver weights. Data are means Ϯ SE. *P Ͻ 0.05. Data are mean Ϯ SE values of absolute weights of fetal heart tissues and fetal heart-to-body weight ratios for no. of fetuses indicated in parentheses. IGF-I, insulin-like growth factor-I; LVFW, left ventricular free wall; RVFW, right ventricular free wall; IVS, interventricular septum. infusion compared with fetuses subsequently infused with IGF-I (P Ͻ 0.05), but they did not change throughout the experimental period in either group of fetuses. Plasma lactate was similar in both groups before the start of infusion but was increased by the end of the treatment with IGF-I (Table 4) .
DISCUSSION
We have shown for the first time that in late gestation female fetal sheep have larger and more mature myocytes than males. IGF-I treatment was associated with increased myocyte volumes, but this was confined to male fetuses. This was evident several days after cessation of treatment, showing that these effects of IGF-I were persistent. IGF-I treatment was also associated with altered cardiac cell cycle activity, which is consistent with the in vitro observations of Sundgren et al. (21) that IGF-I stimulates cardiac growth through hyperplasia. Together these observations suggest that IGF-I can promote cardiac growth in the male fetus in late gestation through both hypertrophy and hyperplasia.
We found no persistent effect of IGF-I treatment of the fetus on the proportion of binucleated cells. This contrasts with the study of Sundgren et al. (21) , in which in vivo treatment of fetal sheep with long R3 IGF-I, which has a lower affinity for IGFBPs and biopotency equivalent to the doses of IGF-I that we used, increased the proportion of uninucleated myocytes. However, in that study (21) , long R3 IGF-I was infused for 7 days and fetuses were immediately euthanized. Thus there was no time for any transient cardiac effects of IGF-I to be overridden by subsequent physiological demands on the heart. Our shorter infusion time of 4 days, and the fact that we harvested fetal hearts 3 days after cessation of IGF-I treatment, may have allowed any transient acute effects of IGF-I treatment to abate. The half-life of IGF-I in the circulation is ϳ20 h. Thus by 3 days after the end of the infusion, levels of IGF-I in fetal plasma were normal (Fig. 2) . Data are mean Ϯ SE percentages for n fetuses of nuclei of cells in different stages of cell cycle as determined by flow cytometry cell sorting technique ͓fluorescence-activated cell sorting (FACS)͔. Percentage of nuclei that incorporated 5-bromo-2Ј-deoxyuridine (BrdU) ͓%BrdU; n ϭ 4 for vehicle (2 male, 2 female); n ϭ 7 for IGF-I (3 male, 4 female)͔ and percentage of nuclei of cells in G0 and G1 phases (%G0G1), G2 and M phases (%G2M), and S phase (%S) ͓n ϭ 6 for vehicle (2 male, 4 female); n ϭ 7 for IGF-I (3 male and 4 female)͔ from LV and RV walls in vehicle-and IGF-I-infused fetuses are shown. *P Ͻ 0.1, †P Յ 0.05, IGF-I-infused fetuses vs. vehicle-infused fetuses. Data are mean Ϯ SE fetal blood pressures and heart rates on day 4 of infusion for no. of fetuses indicated in parentheses. *P Ͻ 0.05. In all 4 subtypes of cardiac myocytes (uni-and binucleated and LVFW and RVFW), myocyte volumes were larger in control female fetuses than in control male fetuses (P Ͻ 0.001). IGF-I treatment was associated with larger myocyte volumes in male fetuses only (P Յ 0.006), and myocyte volumes therefore did not differ between males and females in IGF-I-treated fetuses. Data are means Ϯ SE; no. of myocytes measured is shown at top of each panel. **P Յ 0.006, ***P Ͻ 0.001.
The fact that fetal heart size was not increased by IGF-I was surprising. In our earlier studies (14) in which IGF-I was administered for longer and up to 7 days at the same dose, fetal heart weight and in particular LVFW weight were increased. In the present study, IGF-I was clearly bioactive and exerted anabolic effects including increased kidney weights in both female and male fetal sheep and increased spleen weights in male fetuses. Although the 4-day infusion of IGF-I was associated with a nonsignificant increase in cell cycle activity in fetal RV myocytes (Table 2) , the duration of treatment was not sufficient to drive hyperplastic growth of the heart to the same extent as seen with longer periods of infusion of long R3 IGF-I. Furthermore, our studies examined the cell cycle activity of all cardiac cell nuclei after in vivo injection of BrdU. Sundgren et al. (21) studied effects of long R3 IGF-I on myocyte BrdU uptake in vitro. It could also be possible that in the present study IGF-I stimulated hyperplastic growth of both uninucleated and binucleated myocytes to the same extent, so that there was no change in the proportions of uni-and binucleated myocytes, or there was proliferation and simultaneous terminal differentiation of uninucleated myocytes. Also, Jonker et al. (8) showed that uninucleated cells can "bud" off from the ends of the multinucleated myocyte, so it is possible that multinucleated cells may contribute to hyperplastic growth of the heart. IGF-I and long R3 IGF-I may also have had slightly different biological effects on fetal organ development. For example, IGF-I treatment of the fetal sheep is associated with consistent increases in kidney weight (Refs. 12, 14 and this study) but inconsistent effects on heart weight (Ref. 14 and this study), while Sundgren et al. (21) found that the effect of long R3 IGF-I on kidney weight was variable and could only be detected by expressing kidney weight relative to body weight, whereas there was a large and consistent (35%) increase in heart weight. This may reflect differences in association with IGFBPs between the analog long R3 IGF-I and IGF-I used in the present study and the modulatory actions of either locally produced or circulating binding proteins on the exogenous forms administered between kidneys and heart.
It was surprising that there was sexual dimorphism both in the size and nucleation of cardiac myocytes and in organ growth and cardiomyocyte responses of the fetuses to IGF-I in the present study. IGF-I treatment is consistently associated with an increase in fetal spleen weight (9, 10, 23) . Here we observed increased spleen weights only in IGF-I-treated male fetal sheep, although kidney weights were increased in both male and female IGF-I-treated animals (Fig. 3) . The increase in spleen weight was probably related to the stimulatory effects of IGF-I on lymphopoiesis (23) .
Unexpectedly, female fetal sheep in this cohort had more binucleated myocytes and larger cardiac myocytes than males. In fetal sheep the number of binucleated myocytes increases with increasing gestation age, so that by 145 days of gestation they make up ϳ75% of the cardiac myocyte population. They are larger than uninucleated myocytes (2) and have an increased volume of myofibrils (5, 11) . It is interesting to speculate that these larger, more mature myocytes might be more capable of maintaining cardiac output in the preterm female. If this is the case, and these morphological differences in female and male immature myocytes are present in human fetuses at the equivalent stage of gestation, they may contribute to the better survival of preterm females compared with preterm males (24) . Female neonatal rat hearts (3-5 days old) showed more rapid recovery rates and recoveries of ratepressure products and contractile function as well as delayed onset of contracture than males after global ischemia (1) .
In the present study, not only did male and female cardiac myocyte volumes differ in control fetal sheep but IGF-I treatment increased myocyte size only in male cells. We do not know whether this has been reported before, although it is known that IGF-I affects the expression of sex-specific hepatic enzymes (19) . It is interesting that IGF-I treatment increased the individual cell volumes of the four myocyte subtypes of male fetal sheep to sizes similar to those of myocytes isolated from female IGF-I-treated sheep (which were not in fact any different from myocyte volumes of vehicle-infused female sheep; Fig. 5 ). The arterial pressures of IGF-I-treated male fetuses were not higher than those of vehicle-infused animals, there were no differences in the rate-pressure products between male and female control fetuses, and these were not altered by IGF-I in males or females. Therefore, the sex-specific effects of IGF-I treatment on cardiac myocyte volumes were not due to any effects of arterial pressure or cardiac load. Even though the rate-pressure products of IGF-I-treated male fetal sheep were less than those of similarly treated female fetal sheep (P Ͻ 0.03), their myocyte volumes were similar to those of female IGF-I-treated female sheep, further suggesting that the increased cell volumes of male IGF-I-treated fetal sheep are the result of IGF-I treatment rather than a response to increased physiological demand.
Previously, Sundgren et al. (21) found no change in cardiac myocyte size in fetal sheep treated with long R3 IGF-I. However, they measured myocyte area (21), while we measured myocyte volume, which provides a more sensitive measure of cardiac hypertrophy. IGF-I may expand the volume of myocytes by increasing glucose uptake and protein synthesis. IGF-I is known to increase glucose uptake and the myofibrillar contents of ventricular myocytes (6, 10) .
We have shown (15) that IGF-I treatment of the fetal sheep is associated with substantial increases in plasma renin activity. While renin mRNA is not found in the fetal sheep heart (unpublished observations), circulating renin can be taken up by the cardiac mannose-6-phosphate/IGF-II receptor (IGF-2R). Expression and immunoreactivity of the IGF-II receptor are high in the fetal bovine heart from midgestation onward (17) . Uptake of renin by the fetal heart could activate a fetal intracardiac renin-angiotensin system, because renin's substrate, angiotensinogen, is expressed in fetal cardiac tissue and its expression is regulated by hormones such as cortisol (13) . Angiotensin II has marked effects on cardiac morphology (22) . Thus by stimulating renin release from the fetal kidney, IGF-I could affect the growth and development of the fetal heart. It has been shown, for example, that drugs that block the reninangiotensin system (such as enalapril) have adverse effects on postnatal development of the heart (4).
In summary, IGF-I treatment of the fetal sheep in late gestation was associated with increased myocyte volume in male but not female fetal sheep, suggesting promotion of cardiac growth by hypertrophy. Female fetal sheep had larger myocytes and a greater proportion of binucleated cardiac myocytes than males, suggesting that myocyte maturation may occur earlier in females than in males. Greater functional maturity could account for the increased resistance of the preterm female neonate to hypoxia. This may also explain in part the male sex-specific responsiveness of cardiac hypertrophy to IGF-I in late gestation. If IGF-I-stimulated cardiomyocyte growth is accompanied by maturation of contractile function, IGF-I may be a potential therapeutic agent for maintaining cardiac output in preterm males.
